Samsung Biologics has completed a strategic acquisition of PolyPeptide, a leading Swiss peptide manufacturer, for $1.8 billion. This major investment represents Samsung's continued commitment to expanding its global biopharmaceutical footprint and strengthening its capabilities in specialized peptide production. The takeover underscores a broader trend of South Korean conglomerates pursuing international growth through targeted M&A activities, positioning Samsung to compete more effectively in the competitive specialty biotech sector.

Summary auto-generated by AI from the original publisher's content. Editorial standards.